Cerca nel sito
GemelliGenerator
Dr. Anna Fagotti
Dott. Davide Guido PhD, Dott. Luciano Giaco’ PhD, Dott.ssa Ivana Conti, Ing. Tina Pasciuto, Paolo Casu
The aim of the research is to evaluate the synergism between the genetic marker BRCA and histopathologic features (i.e., molecular markers), in patients with primary advanced ovarian cancer, by considering BRCA as a modification effect in relation to the overall survival (OS), disease free survival (DFS) and platinum resistance. Associations between genetic and molecular markers are also evaluated. Complex statistical modelling is applied to generate evidences.
What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
https://doi.org/10.3390/cancers 14194588
Title (first study): Clinical-pathological features and BRCA 1\2 mutation in women with epithelial ovarian cancer: is there a molecular landmark?
Title (second study): Association between clinical-pathological features and BRCA 1\2 mutation in women with epithelial ovarian cancer
